Authors
Loading...
Supports preferring non-beta-blocker antihypertensives initially; confirms inferiority while underscoring high bias in existing trials.
Key points are not available for this paper at this time.
Wiysonge et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: